DOCSLIB.ORG

BENZODIAZEPINE DEPENDENCE & PSYCHOPATHOLOGY AMONG HEROIN USERS in SYDNEY Joanne Ross & Shane Darke. NDARC Technical Re

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BENZODIAZEPINE DEPENDENCE & PSYCHOPATHOLOGY AMONG HEROIN USERS in SYDNEY Joanne Ross & Shane Darke. NDARC Technical Re BENZODIAZEPINE DEPENDENCE & PSYCHOPATHOLOGY AMONG HEROIN USERS IN SYDNEY Joanne Ross & Shane Darke. NDARC Technical Report No. 50 Technical Report No. 50 BENZODIAZEPINE DEPENDENCE AND PSYCHOPATHOLOGY AMONG HEROIN USERS IN SYDNEY Joanne Ross & Shane Darke National Drug & Alcohol Research Centre, University of New South Wales, Sydney. ISBN: 0 947229 80 9 NDARC 1997 TABLE OF CONTENTS ACKNOWLEDGMENTS ..............................................................................................................................................................vi EXECUTIVE SUMMARY ........................................................................................................................................................ viivii 1.0 INTRODUCTION..................................................................................................................................................................1 1.1 Study Aims................................................................................................................................................................................................................................2 2.0 METHOD.....................................................................................................................3 2.1 Procedure..................................................................................................................................................................................................................................3 2.2 Structured Interview..............................................................................................................................................................................3 2.2.1 Demographic characteristics.....................................................................................................................3 2.2.2 Drug use history.............................................................................................................................................................................3 2.2.3 Heroin dependence.....................................................................................................................................................................4 2.2.4 Benzodiazepine use history...............................................................................................................................4 2.2.5 Benzodiazepine dependence................................................................................................................................4 2.2.6 Psychological functioning........................................................................................................................4 2.3 Analyses.........................................................................................................................................................................................................................................4 3.0 RESULTS......................................................................................................................5 3.1 Sample Characteristics.........................................................................................................................................................................5 3.2 Benzodiazepine Use............................................................................................................................................................................................7 3.3 Other Drug Use...........................................................................................................................................................................................................9 3.4 Benzodiazepine Dependence....................................................................................................................................................10 3.5 Prevalence of DSM-III-R Symptoms of Benzodiazepine Dependence 12 3.6 Determining an Appropriate Cut-Off Mark on the SDS for Benzodiazepine Dependence....................................................................................................................................................14 3.7 Prevalence of Anxiety and Depressive Disorders.........................................................15 3.8 Order of Onset of Anxiety, Depressive Disorders and Regular Benzodiazepine Use..........................................................................................................................................................................................16 3.9 Prevalence of Other Substance Dependence Diagnoses...........................18 4.0 DISCUSSION...........................................................................................................20 4.1 Major Findings.......................................................................................................................................................................................................20 4.2 Benzodiazepine Use........................................................................................................................................................................................20 4.3 Benzodiazepine Dependence..................................................................................................................................................20 4.4 Use of the SDS for Assessing Benzodiazepine Dependence Among Heroin Users...................................................................................................................................................................................21 4.5 Other Drug Use and Dependencies........................................................................................................................21 4.6 Diagnoses of Anxiety and Depression.....................................................................................................22 4.7 The Onset of Psychiatric Disorders and Regular Benzodiazepine Use........................................................................................................................................................................................22 4.8 Implications...................................................................................................................................................................................................................23 4.9 Conclusions.................................................................................................................................................................................................................23 5.0 REFERENCES............................................................................................................25 LOCATION OF TABLES & FIGURES Table 1: Demographic Characteristics of 222 Heroin Users.........................6 Table 2: History of Benzodiazepine Use Among Current Users.............8 Table 3: Other Drug Use...............................................................................................................................................................................10 Table 4: Multiple Logistic Regression Predicting a Lifetime CIDI Diagnosis of Benzodiazepine Dependence..................................................................11 Table 5: Prevalence of DSM-III-R Benzodiazepine Dependence Symptoms Among Current Benzodiazepine Users................................13 Table 6: Validity of Various Cut-Off Scores on the SDS for Assessing Benzodiazepine Dependence Among Heroin Users................................15 Table 7: Lifetime Prevalence of Anxiety and Depressive Disorders Among Subjects With and Without a Lifetime Diagnosis of Benzodiazepine Dependence...............................................................................................................16 Table 8: Proportions of Regular Benzodiazepine Users with Anxiety or Depressive Disorders in which the Diagnosis Preceded the Onset of Regular Benzodiazepine Use.....................17 Table 9: Lifetime Prevalence of Substance Dependence Diagnoses Among Subjects with and without a Benzodiazepine Dependence History............................................................................................................................................................19 Figure 1: Receiver Operating Characteristic (ROC) Curve for the SDS in Assessing Benzodiazepine Dependence Among Heroin Users.............................................................................................................................................................................................14 ACKNOWLEDGMENTS The authors would like to thank the following organisations for their assistance in this study: Kullaroo Clinic, Coopers Cottage, St Marys' Needle Exchange and Liverpool Hospital Drug and Alcohol Service. In particular, we would like to thank Tony Clifford, Mario Fantini, Dr Tony Gill, Suzanne van Opdorp, Anne- Marie Ryan and Sandra Sunjic. EXECUTIVE SUMMARY The current study examined the prevalence of benzodiazepine dependence and psychopathology among heroin users in Sydney. Using the Composite International Diagnostic Interview (CIDI), 222 heroin users were assessed for lifetime and current drug dependencies, anxiety and depressive disorders. Benzodiazepines had been used by 91% of the sample, of whom 26% met the criteria for a lifetime diagnosis of dependence. Two thirds of the sample had used benzodiazepines in the preceding 12 months, of whom
Load more

Recommended publications
  • Substance Abuse and Dependence
    9 Substance Abuse and Dependence CHAPTER CHAPTER OUTLINE CLASSIFICATION OF SUBSTANCE-RELATED THEORETICAL PERSPECTIVES 310–316 Residential Approaches DISORDERS 291–296 Biological Perspectives Psychodynamic Approaches Substance Abuse and Dependence Learning Perspectives Behavioral Approaches Addiction and Other Forms of Compulsive Cognitive Perspectives Relapse-Prevention Training Behavior Psychodynamic Perspectives SUMMING UP 325–326 Racial and Ethnic Differences in Substance Sociocultural Perspectives Use Disorders TREATMENT OF SUBSTANCE ABUSE Pathways to Drug Dependence AND DEPENDENCE 316–325 DRUGS OF ABUSE 296–310 Biological Approaches Depressants Culturally Sensitive Treatment Stimulants of Alcoholism Hallucinogens Nonprofessional Support Groups TRUTH or FICTION T❑ F❑ Heroin accounts for more deaths “Nothing and Nobody Comes Before than any other drug. (p. 291) T❑ F❑ You cannot be psychologically My Coke” dependent on a drug without also being She had just caught me with cocaine again after I had managed to convince her that physically dependent on it. (p. 295) I hadn’t used in over a month. Of course I had been tooting (snorting) almost every T❑ F❑ More teenagers and young adults die day, but I had managed to cover my tracks a little better than usual. So she said to from alcohol-related motor vehicle accidents me that I was going to have to make a choice—either cocaine or her. Before she than from any other cause. (p. 297) finished the sentence, I knew what was coming, so I told her to think carefully about what she was going to say. It was clear to me that there wasn’t a choice. I love my T❑ F❑ It is safe to let someone who has wife, but I’m not going to choose anything over cocaine.
    [Show full text]
  • GABA Systems, Benzodiazepines, and Substance Dependence
    Robert J. Malcolm GABA Systems, Benzodiazepines, and Substance Dependence Robert J. Malcolm, M.D. Alterations in the γ-aminobutyric acid (GABA) receptor complex and GABA neurotransmission influence the reinforcing and intoxicating effects of alcohol and benzodiazepines. Chronic modulation of the GABAA-benzodiazepine receptor complex plays a major role in central nervous system dysregulation during alcohol abstinence. Withdrawal symptoms stem in part from a decreased GABAergic inhibitory function and an increase in glutamatergic excitatory function. GABAA recep- tors play a role in both reward and withdrawal phenomena from alcohol and sedative-hypnotics. Although less well understood, GABAB receptor complexes appear to play a role in inhibition of moti- vation and diminish relapse potential to reinforcing drugs. Evidence suggests that long-term alcohol use and concomitant serial withdrawals permanently alter GABAergic function, down-regulate ben- zodiazepine binding sites, and in preclinical models lead to cell death. Benzodiazepines have substan- tial drawbacks in the treatment of substance use–related disorders that include interactions with alco- hol, rebound effects, alcohol priming, and the risk of supplanting alcohol dependency with addiction to both alcohol and benzodiazepines. Polysubstance-dependent individuals frequently self-medicate with benzodiazepines. Selective GABA agents with novel mechanisms of action have anxiolytic, anticonvulsant, and reward inhibition profiles that have potential in treating substance use and with- drawal and enhancing relapse prevention with less liability than benzodiazepines. The GABAB receptor agonist baclofen has promise in relapse prevention in a number of substance dependence dis- orders. The GABAA and GABAB pump reuptake inhibitor tiagabine has potential for managing alcohol and sedative-hypnotic withdrawal and also possibly a role in relapse prevention.
    [Show full text]
  • Barriers and Solutions to Addressing Tobacco Dependence in Addiction Treatment Programs
    Barriers and Solutions to Addressing Tobacco Dependence in Addiction Treatment Programs Douglas M. Ziedonis, M.D., M.P.H.; Joseph Guydish, Ph.D., M.P.H.; Jill Williams, M.D.; Marc Steinberg, Ph.D.; and Jonathan Foulds, Ph.D. Despite the high prevalence of tobacco use among people with substance use disorders, tobacco dependence is often overlooked in addiction treatment programs. Several studies and a meta-analytic review have concluded that patients who receive tobacco dependence treatment during addiction treatment have better overall substance abuse treatment outcomes compared with those who do not. Barriers that contribute to the lack of attention given to this important problem include staff attitudes about and use of tobacco, lack of adequate staff training to address tobacco use, unfounded fears among treatment staff and administration regarding tobacco policies, and limited tobacco dependence treatment resources. Specific clinical-, program-, and system-level changes are recommended to fully address the problem of tobacco use among alcohol and other drug abuse patients. KEY WORDS: Alcohol and tobacco; alcohol, tobacco, and other drug (ATOD) use, abuse, dependence; addiction care; tobacco dependence; smoking; secondhand smoke; nicotine; nicotine replacement; tobacco dependence screening; tobacco dependence treatment; treatment facility-based prevention; co-treatment; treatment issues; treatment barriers; treatment provider characteristics; treatment staff; staff training; AODD counselor; client counselor interaction; smoking cessation; Tobacco Dependence Program at the University of Medicine and Dentistry of New Jersey obacco dependence is one of to the other. The common genetic vul­ stance use was considered a potential the most common substance use nerability may be located on chromo­ trigger for the primary addiction.
    [Show full text]
  • Meth/Amphetamine Use and Associated HIV: Implications for Global Policy and Public Health
    International Journal of Drug Policy 21 (2010) 347–358 Contents lists available at ScienceDirect International Journal of Drug Policy journal homepage: www.elsevier.com/locate/drugpo Review Meth/amphetamine use and associated HIV: Implications for global policy and public health Louisa Degenhardt ∗,1, Bradley Mathers 2, Mauro Guarinieri 3, Samiran Panda 4, Benjamin Phillips 5, Steffanie A. Strathdee 6, Mark Tyndall 7, Lucas Wiessing 8, Alex Wodak 9, John Howard 10, the Reference Group to the United Nations on HIV and injecting drug use National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia article info abstract Article history: Amphetamine type stimulants (ATS) have become the focus of increasing attention worldwide. There are Received 29 May 2009 understandable concerns over potential harms including the transmission of HIV. However, there have Received in revised form 30 October 2009 been no previous global reviews of the extent to which these drugs are injected or levels of HIV among Accepted 24 November 2009 users. A comprehensive search of the international peer-reviewed and grey literature was undertaken. Multiple electronic databases were searched and documents and datasets were provided by UN agencies and key experts from around the world in response to requests for information on the epidemiology of use. Keywords: Amphetamine or methamphetamine (meth/amphetamine, M/A) use was documented in 110 countries, Methamphetamine Amphetamine and injection in 60 of those. Use may be more prevalent in East and South East Asia, North America, South HIV Africa, New Zealand, Australia and a number of European countries. In countries where the crystalline Injecting form is available, evidence suggests users are more likely to smoke or inject the drug; in such countries, Epidemiology higher levels of dependence may be occurring.
    [Show full text]
  • Evidence-Based Guidelines for the Pharmacological Management of Substance Abuse, Harmful Use, Addictio
    444324 JOP0010.1177/0269881112444324Lingford-Hughes et al.Journal of Psychopharmacology 2012 BAP Guidelines BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, Journal of Psychopharmacology 0(0) 1 –54 harmful use, addiction and comorbidity: © The Author(s) 2012 Reprints and permission: sagepub.co.uk/journalsPermissions.nav recommendations from BAP DOI: 10.1177/0269881112444324 jop.sagepub.com AR Lingford-Hughes1, S Welch2, L Peters3 and DJ Nutt 1 With expert reviewers (in alphabetical order): Ball D, Buntwal N, Chick J, Crome I, Daly C, Dar K, Day E, Duka T, Finch E, Law F, Marshall EJ, Munafo M, Myles J, Porter S, Raistrick D, Reed LJ, Reid A, Sell L, Sinclair J, Tyrer P, West R, Williams T, Winstock A Abstract The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people. Keywords Substance misuse, addiction, guidelines, pharmacotherapy, comorbidity Introduction guidelines (e.g.
    [Show full text]
  • Treatment of Patients with Substance Use Disorders Second Edition
    PRACTICE GUIDELINE FOR THE Treatment of Patients With Substance Use Disorders Second Edition WORK GROUP ON SUBSTANCE USE DISORDERS Herbert D. Kleber, M.D., Chair Roger D. Weiss, M.D., Vice-Chair Raymond F. Anton Jr., M.D. To n y P. G e o r ge , M .D . Shelly F. Greenfield, M.D., M.P.H. Thomas R. Kosten, M.D. Charles P. O’Brien, M.D., Ph.D. Bruce J. Rounsaville, M.D. Eric C. Strain, M.D. Douglas M. Ziedonis, M.D. Grace Hennessy, M.D. (Consultant) Hilary Smith Connery, M.D., Ph.D. (Consultant) This practice guideline was approved in December 2005 and published in August 2006. A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available in the Psychiatric Practice section of the APA web site at www.psych.org. 1 Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. AMERICAN PSYCHIATRIC ASSOCIATION STEERING COMMITTEE ON PRACTICE GUIDELINES John S. McIntyre, M.D., Chair Sara C. Charles, M.D., Vice-Chair Daniel J. Anzia, M.D. Ian A. Cook, M.D. Molly T. Finnerty, M.D. Bradley R. Johnson, M.D. James E. Nininger, M.D. Paul Summergrad, M.D. Sherwyn M.
    [Show full text]
  • Circadian- and Sex-Dependent Increases in Intravenous Cocaine Self-Administration in Npas2 Mutant Mice
    bioRxiv preprint doi: https://doi.org/10.1101/788786; this version posted October 1, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Circadian- and sex-dependent increases in intravenous cocaine self-administration in Npas2 mutant mice Lauren M. DePoy1,2, Darius D. Becker-Krail1,2, Neha M. Shah1, Ryan W. Logan1,2,3, Colleen A. McClung1,2,3 1Department of Psychiatry, Translational Neuroscience Program, University of Pittsburgh School of Medicine 2Center for Neuroscience, University of Pittsburgh 3Center for Systems Neurogenetics of Addiction, The Jackson Laboratory Contact: Lauren DePoy, PhD 450 Technology Dr. Ste 223 Pittsburgh, PA 15219 412-624-5547 [email protected] Running Title: Increased self-administration in female Npas2 mutant mice Key words: circadian, sex-differences, cocaine, self-administration, addiction, Npas2 Abstract: 250 Body: 3996 Figures: 6 Tables: 1 Supplement: 3 Figures Acknowledgements: We Would like to thank Mariah Hildebrand and Laura Holesh for animal care and genotyping. We thank Drs. Steven McKnight and David Weaver for providing the Npas2 mutant mice. This work was funded by the National Institutes of Health: DA039865 (PI: Colleen McClung, PhD) and DA046117 (PI: Lauren DePoy). Disclosures: All authors have no financial disclosures or conflicts of interest to report. 1 bioRxiv preprint doi: https://doi.org/10.1101/788786; this version posted October 1, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Background: Addiction is associated With disruptions in circadian rhythms.
    [Show full text]
  • Randomized Controlled Trial of Dexamphetamine Maintenance for the Treatment of Methamphetamine
    RESEARCH REPORT doi:10.1111/j.1360-0443.2009.02717.x Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependenceadd_2717 146..154 Marie Longo1, Wendy Wickes1, Matthew Smout1, Sonia Harrison1, Sharon Cahill1 & Jason M. White1,2 Pharmacotherapies Research Unit, Drug and Alcohol Services South Australia, Norwood, South Australia, Australia1 and Discipline of Pharmacology, University of Adelaide, Adelaide, South Australia, Australia2 ABSTRACT Aim To investigate the safety and efficacy of once-daily supervised oral administration of sustained-release dexam- phetamine in people dependent on methamphetamine. Design Randomized, double-blind, placebo-controlled trial. Participants Forty-nine methamphetamine-dependent drug users from Drug and Alcohol Services South Australia (DASSA) clinics. Intervention Participants were assigned randomly to receive up to 110 mg/day sustained- release dexamphetamine (n = 23) or placebo (n = 26) for a maximum of 12 weeks, with gradual reduction of the study medication over an additional 4 weeks. Medication was taken daily under pharmacist supervision. Measurements Primary outcome measures included treatment retention, measures of methamphetamine consump- tion (self-report and hair analysis), degree of methamphetamine dependence and severity of methamphetamine withdrawal. Hair samples were analysed for methamphetamine using liquid chromatography-mass spectrometry. Findings Treatment retention was significantly different between groups, with those who received dexamphetamine remaining in treatment for an average of 86.3 days compared with 48.6 days for those receiving placebo (P = 0.014). There were significant reductions in self-reported methamphetamine use between baseline and follow-up within each group (P < 0.0001), with a trend to a greater reduction among the dexamphetamine group (P = 0.086).
    [Show full text]
  • Management of Acute Withdrawal and Detoxification for Adults Who Misuse Methamphetamine: a Review of the Clinical Evidence and Guidelines
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Management of Acute Withdrawal and Detoxification for Adults who Misuse Methamphetamine: A Review of the Clinical Evidence and Guidelines Service Line: Rapid Response Service Version: 1.0 Publication Date: February 08, 2019 Report Length: 28 Pages Authors: Michelle Clark, Robin Featherstone Cite As: Management of Acute Withdrawal and Detoxification for Adults who Misuse Methamphetamine: A Review of the Clinical Evidence and Guidelines. Ottawa: CADTH; 2019 Feb. (CADTH rapid response report: summary with critical appraisal). ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect.
    [Show full text]
  • Cocaine (Canadian Drug Summary)
    www.ccsa.ca • www.ccdus.ca Winter 2019 Canadian Drug Summary Cocaine Key Points The percentage of cocaine use in the Canadian population is low (~2%). The rate of past year cocaine use in older youth (ages 20-24) is increasing. Despite low prevalence of consumption, cocaine is responsible for the highest costs to the criminal justice system of any substance in Canada following alcohol. Introduction Cocaine is derived from the coca shrub grown primarily in South America. Extracting cocaine from the coca plant involves soaking the coca leaves in chemical solvents and crushing the leaves to form a paste. This paste is then treated with oxidizing agents and acids to create cocaine hydrochloride, commonly referred to as cocaine.1 Cocaine is a white powder that is often mixed with substances similar in appearance, such as corn starch. This powder can be taken through the nose by snorting or it can be dissolved and injected.2 Commonly used street names for cocaine include “coke,” “coca,” “coco,” “snow,” “Charlie,” “dust,” “snowflake” and “powder.”3 Freebase cocaine is made when the hydrochloride is removed from cocaine hydrochloride, thus liberating cocaine to a “freebase.” This is done to create a smokeable form of cocaine, but the technique for producing freebase cocaine can be very hazardous.1 A more common and less hazardous way to create smokeable cocaine is to dissolve cocaine in a mixture of water and baking soda to form whitish, opaque crystals. These crystals are commonly referred to as crack or “rock,” as the crystals look like rocks.4 When the crack “rock” is heated, it makes a crackling sound, thus the term “crack.”3 Crack or freebase cocaine can be smoked or dissolved and injected.
    [Show full text]
  • Therapy Manuals for Drug Addiction. Manual 1
    i ACKNOWLEDGMENTS The development of earlier versions of this manual was supported by several research grants from the National Institute on Drug Abuse. The current manual was written by Dr. Kathleen Carroll of Yale University under Contract Number N-OIDA-4-2205 with the National Institute on Drug Abuse. Dr. Lisa Onken, the NIDA Project Officer, offered valuable guidance and comments throughout the preparation of this manual. The material presented in this manual is the result of a program of research by Dr. Kathleen Carroll and Dr. Bruce Rounsaville and their colleagues at Yale University. The development of this therapy model for treatment of drug abuse drew extensively from the work of Alan Marlatt and others (Marlatt and Gordon 1985; Chancy et al. 1978; Jaffe et al. 1988; Ito et al. 1984). The structure and sequence of sessions presented in this therapy model was partially developed by work on Project MATCH published by the National Institute on Alcohol Abuse and Alcoholism (Kadden et al. 1992) and the manual developed by Peter Monti and his colleagues (1989). These sources are particularly reflected here in the a skills-training material, and we have acknowledged the original sources in each of those sections. Yale University Research Team Coinvestigators: Bruce Rounsaville, M.D. Roseann Bisighini, M.S. Charla Nich, M.S. Monica Canning-Ball Sam Ball, Ph.D. Joanne Corvino, M.P.H. Lisa Fenton, Psy.D. Kea Cox Frank Gawin, M.D. Lynn Gordon, R.N. Tom Kosten, M.D. Tami Frankforter Elinor McCance-Katz, M.D., Ph.D. jenniffer Owler Douglas Ziedonis, M.D.
    [Show full text]
  • Heterogeneity of Stimulant Dependence: a National Drug Abuse Treatment Clinical Trials Network Study
    The American Journal on Addictions, 18: 206–218, 2009 Copyright C American Academy of Addiction Psychiatry ISSN: 1055-0496 print / 1521-0391 online DOI: 10.1080/10550490902787031 Heterogeneity of Stimulant Dependence: A National Drug Abuse Treatment Clinical Trials Network Study Li-Tzy Wu, ScD,1 Dan G. Blazer, MD, PhD,1 Ashwin A. Patkar, MD,1 Maxine L. Stitzer, PhD,2 Paul G. Wakim, PhD,3 Robert K. Brooner, PhD2 1Duke University School of Medicine, Department of Psychiatry and Behavioral Sciences, Duke Clinical Research Institute, Durham, North Carolina 2Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, Maryland 3National Institute on Drug Abuse, Bethesda, Maryland We investigated the presence of DSM-IV subtyping for of disorders has noteworthy advantages because it facilitates dependence on cocaine and amphetamines (with versus with- research, improves communications among clinicians and out physical dependence) among outpatient stimulant users researchers, and serves as a necessary tool for collecting enrolled in a multisite study of the Clinical Trials Network 1 (CTN). Three mutually exclusive groups were identified: and communicating public health statistics. The categorical primary cocaine users (n = 287), primary amphetamine users classification, however, also constitutes a primary limitation (n = 99), and dual users (cocaine and amphetamines; n = because it works best when all members of a given diagnosis 29). Distinct subtypes were examined with latent class and are homogeneous and when there are clear boundaries between logistic regression procedures. Cocaine users were distinct distinct diagnoses.1 from amphetamine users in age and race/ethnicity. There were four distinct classes of primary cocaine users: non- DSM-IV acknowledges this limitation and further suggests dependence (15%), compulsive use (14%), tolerance and the presence of heterogeneity among individuals who share compulsive use (15%), and physiological dependence (toler- a diagnosis.
    [Show full text]